Kirsty (Insulin Aspart)

Insulin aspart binds to insulin receptors on muscle, fat, and liver cells, activating intracellular pathways that increase glucose uptake and reduce hepatic glucose production. This rapid action lowers circulating glucose shortly after injection, mimicking the body’s natural insulin response to meals.

The dose of Kirsty is individualized. A qualified prescriber determines the amount, timing, and frequency based on the patient’s blood‑glucose patterns, meal schedule, and overall treatment plan. Patients should follow the prescribing clinician’s instructions and not adjust the dose on their own.

Safety of insulin aspart in pregnancy or lactation should be evaluated by a healthcare professional. Insulin is generally considered the preferred glucose‑lowering therapy in pregnancy, but the prescriber will weigh potential benefits and risks before recommending Kirsty for a pregnant or nursing individual.

To order Kirsty, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Kirsty (insulin aspart) is a rapid‑acting analog with an onset of action within 10‑20 minutes, similar to other fast insulins such as insulin lispro and insulin glulisine. All provide mealtime glucose control, but subtle differences in pharmacokinetic profiles may influence individual patient preference and dosing schedules as determined by the prescriber.

Kirsty should be stored in a refrigerator at 2‑8 °C, protected from light, and must not be frozen or shaken. Once in use, the vial or pen can be kept at controlled room temperature (up to 30 °C) for a limited period, typically up to 28 days, as indicated on the product label.

Kirsty is administered by subcutaneous injection, usually into the abdomen, thigh, or upper arm. The injection should be given shortly before a meal, following the dose prescribed by the healthcare provider. Proper injection technique and site rotation help reduce the risk of local reactions.

The most serious risks include severe hypoglycaemia, which can cause confusion, loss of consciousness, or seizures, and allergic reactions ranging from rash to anaphylaxis. Patients should be educated on recognising symptoms, have a rapid‑acting carbohydrate source available, and seek immediate medical attention if a serious reaction occurs.

Kirsty is contraindicated in individuals with a known hypersensitivity to insulin aspart or any of its excipients. It should also be avoided in patients with severe hypoglycaemia unresponsive to treatment until the underlying cause is resolved. Clinical judgement is required for patients with certain endocrine disorders or those receiving incompatible medications.